Dr. N.R.K. Bio-Tech Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 13-12-2024
- Paid Up Capital ₹ 2.41 Cr
as on 13-12-2024
- Company Age 19 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 25.00 Cr
as on 13-12-2024
- Satisfied Charges ₹ 4.50 M
as on 13-12-2024
- Revenue %
(FY 2022)
- Profit 139.88%
(FY 2022)
- Ebitda -18.21%
(FY 2022)
- Net Worth 196.56%
(FY 2022)
- Total Assets 118.65%
(FY 2022)
About Dr. N.R.K. Bio-Tech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.41 Cr.
The company currently has active open charges totaling ₹25.00 Cr. The company has closed loans amounting to ₹4.50 M, as per Ministry of Corporate Affairs (MCA) records.
Soham Modi, Anand Bhashyakarla, and Milind Ravi serve as directors at the Company.
- CIN/LLPIN
U45100TG2004PTC044950
- Company No.
044950
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Dec 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dr. N.R.K. Bio-Tech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Soham Modi  | Director | 24-Jun-2021 | Current |
| Milind Ravi | Director | 24-Jun-2021 | Current |
| Anand Bhashyakarla | Director | 24-Jun-2021 | Current |
Financial Performance and Corporate Structure Insights of Dr. N.R.K. Bio-Tech.
Dr. N.R.K. Bio-Tech Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 139.88% increase in profit. The company's net worth Soared by an impressive increase of 196.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr. N.R.K. Bio-Tech?
In 2022, Dr. N.R.K. Bio-Tech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 13 Sep 2022 | ₹25.00 Cr | Open |
Others Creation Date: 04 Apr 2020 | ₹4.50 M | Satisfied |
How Many Employees Work at Dr. N.R.K. Bio-Tech?
Dr. N.R.K. Bio-Tech has a workforce of 0 employees as of May 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr. N.R.K. Bio-Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr. N.R.K. Bio-Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
